Ipca Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5yroqsh12hhec5ljh4szfmhb.pdf

Key Takeaways


Unichem Turnaround

Ajit Kumar Jain: "It's a journey, it cannot happen in over a period of 3 to 6 months time. It take a long time. So maybe 1 year, 1.5 years and all"

US Market Re-entry

Harish Kamath: "It is too early to give any guidance. See, nobody is waiting for your product. Even though I have cost competency, I will have to again relaunch product one by one and go on taking market share."

Domestic Formulation


Export & API Headwinds


Generic Business & Subsidiaries


Margins & Costs


Guidance & Commitments

CommitmentSpecificsTimeline
Unichem revenue and margin targetINR2,000 crores revenue, 15% EBITDA margin (INR300 crores EBITDA)By FY26
Unichem margin journeyMargin improvement will continue; full process-to-formulation cycle takes regulatory approvals1 to 1.5 years
US product shipments begin7 products being worked on; shipment may start early part of Q1Early Q1 FY25
US product launches15 to 17 products can be launched from a basket of ~40Over 2 years
Dewas plant commercialization5 to 6 products to get approved, then regular shipments start~6 months
Overall company growthContinuously growing around 10% to 12%From next year onwards
Generic business growth12% to 15% growth on a conservative basis, plus any US businessGoing forward
Branded ROW growthAround 10% growth despite difficultiesNext financial year
Field force expansionNot more than 5% increase in overall field force sizeGoing forward
India formulation growth13% to 14% growth, with 4% to 5% price and rest volumeOngoing

Key Metrics

MetricQ3 FY24
Domestic formulation revenue growth11% for the quarter
Export formulation revenue₹433 cr, +8% YoY from ₹400 cr
Export generic business (UK & other) revenue₹252 cr, +33% YoY from ₹189 cr
API business revenue₹285 cr, declined from ₹329 cr in Q3 FY23
Branded formulation (ROW) revenue₹105 cr, declined from ₹128 cr in Q3 FY23
Institutional antimalarial revenue₹83 cr, declined from ₹277 cr in Q3 FY23
Standalone EBITDA margin18.55%, improved 2.78 ppt from 15.77% in Q3 FY23
Consolidated EBITDA margin (before exchange/exceptional)16.12%, up 1.12 ppt from 15% in Q3 FY23
Material cost to sales ratio (standalone)32.21%, improved from 34.86% in Q3 FY23
Unichem revenue growth43.6% for the quarter
Unichem EBITDA margin8.8%, improved from negative 14.1% in Q3 FY23
Unichem PBT (before exceptional income)~₹16 cr
Domestic chronic segment growth (IQVIA MAT Dec '23)~15.9% vs market growth of 11%
Domestic acute segment growth (IQVIA MAT Dec '23)~11.3% vs market growth of 9.1%
MR productivity~₹4,25,000 per month
Medical rep count~7,000
US products expected for launch in next 12 months8 to 9 products
US products expected for launch over 2 years15 to 17 products
Generic business forward growth guidance12% to 15% (conservative)
Unichem FY26 guidance₹2,000 cr revenue, 15% EBITDA margin